TBR 065
Alternative Names: BIM23B065; TBR 065Latest Information Update: 22 Feb 2022
At a glance
- Originator Ipsen
- Class
- Mechanism of Action Dopamine D2 receptor agonists; Somatostatin receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acromegaly; Pituitary ACTH hypersecretion
Most Recent Events
- 22 Feb 2022 No development reported - Phase-II for Acromegaly (In the elderly, In adults) in Bulgaria, Serbia, Ukraine, Belgium, Belarus and Hungary (SC)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Pituitary-ACTH-Hypersecretion in USA (SC, Injection)
- 03 Jan 2019 Tiburio Therapeutics in-licenses BIM 23B065 from Ipsen